TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06301607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube
Description: The group is given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study: NCT05542706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accompanying caregivers by paramedical team
Description: At each study visit (baseline, one week after hospital discharge, 4-8 weeks after surgery, 8-12 weeks after surgery and 16-20 weeks after surgery), the paramedical team have a dedicated meeting with the caregiver of the patient (at hospital or remote) and teach them the care procedures needed in accompanying the patient and the evaluate the learning progress. The training is adapted to each caregiver, according to his/her motivation and his/her ability. The goal is to have the training regarding the enteral nutrition, prevention of dehydration, pain management.
Study: NCT05531526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR1001
Description: AR1001 Active Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet
Study: NCT05744310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long term mechanical ventilation support
Description: Patients that choose life prolonging treatment with long term mechanical ventilation support

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No long term mechanical ventilation support
Description: Patients that decline life prolonging treatment with long term mechanical ventilation support
Study: NCT05566574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: RP-3500 on Days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: RP-3500 on Days 1-5.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
Study: NCT06569173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LaiKai anti-reflux ureteral stent
Description: Ureteral stents are serving to support the ureter and facilitate urine drainage with an anti-reflux valve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaiKai Ureteral Stent
Description: Ureteral stents are serving to support the ureter and facilitate urine drainage.
Study: NCT05326828

Intervention type: DEVICE
Intervention: CONFIRM Rx implantable cardiac rhythm monitor (Abbott)
Description: Implantation of CONFIRM Rx ICM

Intervention type: DIAGNOSTIC_TEST
Intervention: Systematic etiologic work-up for underlying causes of MINOCA
Description: Intracoronary optical coherence tomography, cardiac magnetic resonance imaging, transesophageal echocardiography, vasospasm testing, thrombophilia screening, Holter ECG (only non-ICM group)

Intervention type: DIAGNOSTIC_TEST
Intervention: Systematic etiologic work-up for underlying causes of MINOCA
Description: Intracoronary optical coherence tomography, cardiac magnetic resonance imaging, transesophageal echocardiography, vasospasm testing, thrombophilia screening, Holter ECG (only non-ICM group)
Study: NCT06559865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: as per group description
Study: NCT05062980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quaratusugene ozeplasmid
Description: Quaratusugene ozeplasmid is an experimental non-viral therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, re-establishing pathways that promote cancer cell death and modulating the immune system response against cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramucirumab
Description: Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Treatment of Choice
Description: Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
Study: NCT06414109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE-Migraine
Description: The BREATHE-Migraine intervention was adapted from the research-supported curriculum, Learning to BREATHE (Broderick, 2021), based on qualitative feedback from adolescents with migraine, their parents, and pediatric headache providers. BREATHE-Migraine includes experiential and didactic exercises designed to address emotion regulation and the stress of living with frequent migraine.
Study: NCT04846036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonlicromanol
Description: Oral administration of sonlicromanol twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo twice daily
Study: NCT06265558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy (NPT)
Description: Negative pressure therapy (NPT) involves placing the surface of a wound under a pressure lower than the ambient atmospheric pressure. To achieve this, a specially designed dressing is connected to a vacuum source and an exudate collection system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Fatty dressing or hydrocellular dressing
Study: NCT06292780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody
Study: NCT05766332

Intervention type: OTHER
Intervention: Clinical Evaluation
Description: Undergo clinical evaluation

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records reviewed
Study: NCT04876092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67856633
Description: Participants will receive JNJ-67856633 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive Ibrutinib orally.
Study: NCT04673357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as SC injection.
Study: NCT05206565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurotization - Autologous Reconstruction with DIEP/TRAM
Description: * Transverse Rectus Abdominis Muscle/Deep Inferior Epigastric Artery Flap Harvest - Prior to elevation of flaps in the suprafascial plane from using loupe magnification to identify medial and lateral row of perforators bilaterally, sensory nerves T10-12 are identified and dissected into the muscle bilaterally to prepare for nerve coaptation, nerves are divided at the level of the fascia where they are pure sensory nerves.~* Chest Intercostal Nerve Harvest - During standard of care chest vessel dissection, intercostal nerves T3-4 are identified. After completion of vein coupling it will be determined whether neurotization can be performed or if autograft. Primary nerve coaptation will be performed if there is adequate length for direct end to end apposition.~* Coaptation of nerve or nerve graft endings will be performed using 9-0 nylon suture in an interrupted fashion.
Study: NCT06081920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 monotherapy
Study: NCT06315296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Follow a time-restricted diet
Study: NCT06337890

Intervention type: PROCEDURE
Intervention: Zero contrast FEVAR
Description: Use of automated CO2 angiographies with Fusion Imaging for zero contrast FEVAR
Study: NCT06315296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive interactive positive reinforcement messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use txt4fasting platform

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling and Surveillance
Description: Receive counseling calls

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo brain MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Use txt4fasting platform

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Message-Based Navigation Intervention
Description: Receive text messages about healthy eating habits and food suggestions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05971238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor vs. outdoor scenes
Description: Light conditions in indoor (artificial light) and outdoor (daylight) settings
Study: NCT06315296

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo brain MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies
Study: NCT04816019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCov-19
Description: A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCov-19
Description: A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCov-19
Description: A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCov-19
Description: A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCov-19
Description: A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCov-19
Description: A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCov-19
Description: A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)
Study: NCT04804995

Intervention type: OTHER
Intervention: There is no intervention.
Description: No intervention.

Intervention type: OTHER
Intervention: There is no intervention.
Description: No intervention.
Study: NCT04777357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT06079177

Intervention type: DEVICE
Intervention: Ultrasound
Description: LUS using B-lines Caval-Aorta index using ultrasound
Study: NCT05938829

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound following the SMFM guidelines
Description: Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery. This information will be captured in our ultrasound reporting software, Viewpoint.

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound following the ISUOG guidelines
Description: Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery, middle cerebral artery, and ductus venosus. This information will be captured in our ultrasound reporting software, Viewpoint.
Study: NCT06572579

Intervention type: PROCEDURE
Intervention: Ultrasound-guided pharmacopuncture treatment
Description: Pharmacopuncture treatment using ultrasound-guidance
Study: NCT05004805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline nasal spray
Description: Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
Study: NCT04980820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No mask
Description: The participant is asked to wear no mask for 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No mask
Description: The participant is asked to wear no mask for 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtering face mask 2 (FFP2)
Description: The participant is asked to wear a FFP2 mask for 1 hour during work.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtering face mask 2 (FFP2)
Description: The participant is asked to wear a FFP2 mask for 1 hour during work.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtering face mask 3 (FFP3)
Description: The participant is asked to wear a FFP3 mask for 1 hour during work.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtering face mask 3 (FFP3)
Description: The participant is asked to wear a FFP3 mask for 1 hour during work.
Study: NCT05473572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluency shaping exercises
Description: Training for prolonged speech, easy onset, light contact and abdominal breathing moving from the level of single words till using short sentences describing pictures
Study: NCT05061277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: A lyophilized powder for solution for injection
Study: NCT05156892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole
Description: 150 mg BD
Study: NCT05932056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Miles de Manos (Thousands of Hands)
Description: Miles de Manos (Thousands of Hands) is a school-based group intervention that incorporates elements of evidence-based behavior management interventions in parent, teacher, and parent-teacher joint sessions.
Study: NCT05291182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-4835
Description: WEE1 inhibitor
Study: NCT06071832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions for family Zoom session
Description: Within both play and reading conditions, we will manipulate the method of enacting the structured activities with the goal of facilitating different types of grandparent-initiated joint attention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions for family Zoom session
Description: Within both play and reading conditions, we will manipulate the method of enacting the structured activities with the goal of facilitating different types of grandparent-initiated joint attention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions for family Zoom session
Description: Within both play and reading conditions, we will manipulate the method of enacting the structured activities with the goal of facilitating different types of grandparent-initiated joint attention.
Study: NCT05156892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Dose Escalation:~Cohort 1: 20 mg OD Cohort 2: 40 mg OD Cohort 3: 60 mg OD~Dose-Expansion: Recommended dose from dose-escalation phase of study
Study: NCT05794984

Intervention type: OTHER
Intervention: Focus group discussions and survey questionnaire
Description: Questions regarding internet and social media usage, as well as telemedicine concept and knowledge. Assessment of the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare. Perceptions for high-quality healthcare access, confidentiality, privacy, and security, will also be explored.
Study: NCT05679531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention
Description: After filling out the patient information form, the patients who met the research criteria were chewed gum for an average of 15 minutes.
Study: NCT06322576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PNT2002
Description: 10 patients will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose).~If opened, Cohort 2 patients will receive 4 cycles, every 8 weeks of 177Lu-PSMA infusion. Other procedures during treatment and follow up may include: physical exam, CT/MRI, PSMA-PET, blood draws, adverse event assessment, and completion of questionnaires.
Study: NCT06528769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given intravenously (IV)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study: NCT04492605

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 capsule per day for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI378 Probiotics
Description: consume 1 capsule per day for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI507 Probiotics
Description: consume 1 capsule per day for 2 months